NON-SMALL-CELL LUNG CARCINOMA
Clinical trials for NON-SMALL-CELL LUNG CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL-CELL LUNG CARCINOMA trials appear
Sign up with your email to follow new studies for NON-SMALL-CELL LUNG CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Lung cancer drug tabrecta® under Real-World watch in south korea
Disease control Recruiting nowThis study is for people with non-small-cell lung cancer that has a specific genetic change (exon 14 skipping mutation). It will track how safe and effective the drug Tabrecta® (Capmatinib) is when used in everyday medical practice. About 44 participants will be followed to recor…
Matched conditions: NON-SMALL-CELL LUNG CARCINOMA
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 16, 2026 23:52 UTC
-
New combo aims to reboot immune attack in resistant cancers
Disease control Recruiting nowThis study tests a two-drug combination (retifanlimab and ruxolitinib) in people with advanced lung or kidney cancer whose disease got worse after standard immunotherapy. The main goal is to find the safest dose of ruxolitinib when given with a fixed dose of retifanlimab, and to …
Matched conditions: NON-SMALL-CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 16, 2026 23:51 UTC
-
Inhaled mist could boost lung cancer treatment before surgery
Disease control Recruiting nowThis study is for people with early-stage non-small cell lung cancer that can be removed with surgery. Researchers want to see if adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy can help kill more cancer cells before surgery. The trial wi…
Matched conditions: NON-SMALL-CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 08, 2026 13:17 UTC
-
New pill targets hard-to-treat cancers with specific gene flaw
Disease control Recruiting nowThis study tests a new experimental drug called PLX-61639 for people with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken as a daily pill and aims to shrink or control the cancer. A…
Matched conditions: NON-SMALL-CELL LUNG CARCINOMA
Phase: PHASE1 • Sponsor: Plexium, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:09 UTC
-
New hope for tough lung cancer: experimental drug takes on standard chemo
Disease control Recruiting nowThis study tests whether a new drug called PF-08046054 works better than the standard chemo docetaxel for people with advanced non-small cell lung cancer that has PD-L1 protein and has stopped responding to other treatments. About 680 adults will be randomly assigned to get one o…
Matched conditions: NON-SMALL-CELL LUNG CARCINOMA
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 08, 2026 13:08 UTC
-
New hope for lung cancer: drug combo trial targets untreated advanced NSCLC
Disease control Recruiting nowThis study tests a new drug, telisotuzumab adizutecan, combined with an immunotherapy (PD-1 inhibitor) for people with advanced non-squamous lung cancer who haven't had prior treatment. The goal is to find the best dose and see if the combo shrinks tumors better than standard car…
Matched conditions: NON-SMALL-CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 05, 2026 12:06 UTC
-
New drug targets rare cancer mutation in 300-patient trial
Disease control Recruiting nowThis study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment …
Matched conditions: NON-SMALL-CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 03, 2026 12:06 UTC
-
New study tracks how a targeted drug combo fights lung cancer in everyday care
Knowledge-focused Recruiting nowThis study watches 100 adults with metastatic non-small cell lung cancer who have certain EGFR gene changes and are already getting amivantamab plus chemotherapy through an early access program. Researchers want to see how long the cancer stays under control in real-world setting…
Matched conditions: NON-SMALL-CELL LUNG CARCINOMA
Sponsor: GFPC Investigation • Aim: Knowledge-focused
Last updated Jun 11, 2026 12:09 UTC